A method for making an NLP (Nanolipidic Particle) assembly population, comprising the steps of: (a) providing a monophasic precursor solution, said monophasic precursor solution made by: solubilizing an amphipathic material comprising phospholipids in a first quantity of non-aqueous solvent; adding a quantity of water to form a turbid suspension; and adding a second quantity of non-aqueous solvent until the turbid suspension is monophasic and has optical clarity at room temperature; (b) diluting said monophasic precursor solution with a one or more aliquots of non-aqueous solvent to form a solvent diluted stock solution in which; (i) said non-aqueous solvent is added in a sequential manner to the monophasic precursor solution before addition of a water-soluble passenger molecule, (ii) said diluting of said monophasic precursor solution with said non-aqueous solvent is at a ratio ranging from about 1 part monophasic precursor solution to about 20 parts non-aqueous solvent to a ratio ranging from about 1 part monophasic precursor solution to about 0.3 parts non-aqueous solvent; (iii) wherein said diluting of said monophasic precursor solution forms a NLP particle population having nanolipidic particles (NLPs) sized from 1 nm to 20 nm, said NLP size decreasing as said non-aqueous solvent concentration increases; (c) admixing a water-soluble passenger molecule with an aqueous solution to form an aqueous passenger solution; and (d) admixing an aliquot of the solvent diluted stock solution with an aliquot of said aqueous passenger solution to form a passenger-loaded NLP assembly population having a mean particle diameter from 30 nm to 200 nm. (a) providing a monophasic precursor solution, said monophasic precursor solution made by: solubilizing an amphipathic material comprising phospholipids in a first quantity of non-aqueous solvent; adding a quantity of water to form a turbid suspension; and adding a second quantity of non-aqueous solvent until the turbid suspension is monophasic and has optical clarity at room temperature; (b) diluting said monophasic precursor solution with a one or more aliquots of non-aqueous solvent to form a solvent diluted stock solution in which; (i) said non-aqueous solvent is added in a sequential manner to the monophasic precursor solution before addition of a water-soluble passenger molecule, (ii) said diluting of said monophasic precursor solution with said non-aqueous solvent is at a ratio ranging from about 1 part monophasic precursor solution to about 20 parts non-aqueous solvent to a ratio ranging from about 1 part monophasic precursor solution to about 0.3 parts non-aqueous solvent; (iii) wherein said diluting of said monophasic precursor solution forms a NLP particle population having nanolipidic particles (NLPs) sized from 1 nm to 20 nm, said NLP size decreasing as said non-aqueous solvent concentration increases; (i) said non-aqueous solvent is added in a sequential manner to the monophasic precursor solution before addition of a water-soluble passenger molecule, (ii) said diluting of said monophasic precursor solution with said non-aqueous solvent is at a ratio ranging from about 1 part monophasic precursor solution to about 20 parts non-aqueous solvent to a ratio ranging from about 1 part monophasic precursor solution to about 0.3 parts non-aqueous solvent; (iii) wherein said diluting of said monophasic precursor solution forms a NLP particle population having nanolipidic particles (NLPs) sized from 1 nm to 20 nm, said NLP size decreasing as said non-aqueous solvent concentration increases; (c) admixing a water-soluble passenger molecule with an aqueous solution to form an aqueous passenger solution; and (d) admixing an aliquot of the solvent diluted stock solution with an aliquot of said aqueous passenger solution to form a passenger-loaded NLP assembly population having a mean particle diameter from 30 nm to 200 nm. <EOS>